Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name B2M LOH
Gene Variant Detail

B2M LOH (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
B2M LOH melanoma predicted - resistant Ipilimumab Clinical Study - Cohort Actionable In a retrospective analysis, B2M loss of heterozygosity (LOH) was significantly enriched in pre-treatment biopsies of melanoma patients who did not respond to Yervoy (ipilimumab) compared to those who responded (20/69, 28.9% vs 4/36, 11.1%, p=0.01), and was associated with poorer overall survival (p=0.01) (PMID: 29070816). 29070816
B2M LOH melanoma predicted - resistant Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, the presence of B2M loss of heterozygosity (LOH) in the pre-treatment biopsies was significantly associated with worse overall survival (p=0.006) in melanoma patients treated with Keytruda (pembrolizumab) (PMID: 29070816). 29070816